公开(公告)号：US09795665B2

公开(公告)日：2017-10-24

申请号：US14421120

申请日：2013-08-13

Applicant: The United States of America as Represented by the Secretary of the Department of Health and Human Services ,  COLORADO SEMINARY, WHICH OWNS AND OPERATES THE UNIVERSITY OF DENVER

Inventor： Eric Bergeron ,  Scott Dusan Pegan ,  Stuart T. Nichol ,  Michelle Kay Deaton

IPC: C12N7/00 ,  A61K39/12 ,  C12Q1/04 ,  A61K39/00

CPC classification number: A61K39/12 ,  A61K2039/5254 ,  C12N7/00 ,  C12N2760/12034 ,  C12Q1/04 ,  G01N2333/175 ,  Y02A50/397

Abstract: The genetically modified nairoviruses of this invention possesses a viral ovarian tumor protease with decreased ability to remove ubiquitin (Ub) and ISG15 tags that the human organism uses to label proteins for removal. Exemplary are Crimean-Congo hemorrhagic fever virus and Erve virus. Unlike complete knockout strains, the modified virus retains enough activity for replication in a human cell line. This creates an immunogenic and non-pathogenic virus that can be used as an effective live vaccine agent for prophylaxis and treatment.

公开(公告)号：US20140050761A1

公开(公告)日：2014-02-20

申请号：US13829105

申请日：2013-03-14

Applicant: Colorado Seminary, which owns and Operates The University of Denver

Inventor： Eric Bergeron ,  Scott Dusan Pegan ,  Stuart T. Nichol ,  Michelle Kay Deaton

IPC: A61K39/12

CPC classification number: A61K39/12 ,  A61K2039/5254 ,  C12N2760/12034 ,  Y02A50/397

Abstract: The genetically modified hemorrhagic fever virus of this invention possesses a viral ovarian tumor protease with decreased ability to remove ubiquitin (Ub) and ISG15 tags that the human organism uses to label proteins for removal. Unlike complete knockout strains, the modified virus retains enough activity for replication in a human cell line. This creates an immunogenic and non-pathogenic virus that can be used as an effective live vaccine agent.

Abstract translation: 本发明的遗传修饰出血热病毒具有病毒性卵巢肿瘤蛋白酶，其具有降低人类生物体用于标记蛋白质去除的泛素（Ub）和ISG15标签的能力降低的能力。 与完全敲除菌株不同，经修饰的病毒在人细胞系中保留足够的活性用于复制。 这产生可用作有效活疫苗剂的免疫原性和非致病性病毒。

公开(公告)号：US09474796B2

公开(公告)日：2016-10-25

申请号：US13829105

申请日：2013-03-14

Applicant: Colorado Seminary, which owns and Operates The University of Denver

Inventor： Eric Bergeron ,  Scott Dusan Pegan ,  Stuart T. Nichol ,  Michelle Kay Deaton

IPC: C12N7/00 ,  A61K39/12 ,  A61K39/00

CPC classification number: A61K39/12 ,  A61K2039/5254 ,  C12N2760/12034 ,  Y02A50/397

Abstract: The genetically modified hemorrhagic fever virus of this invention possesses a viral ovarian tumor protease with decreased ability to remove ubiquitin (Ub) and ISG15 tags that the human organism uses to label proteins for removal. Unlike complete knockout strains, the modified virus retains enough activity for replication in a human cell line. This creates an immunogenic and non-pathogenic virus that can be used as an effective live vaccine agent.

Abstract translation: 本发明的遗传修饰出血热病毒具有病毒性卵巢肿瘤蛋白酶，其具有降低人类生物体用于标记蛋白质去除的泛素（Ub）和ISG15标签的能力降低的能力。 与完全敲除菌株不同，经修饰的病毒在人细胞系中保留足够的活性用于复制。 这产生可用作有效活疫苗剂的免疫原性和非致病性病毒。